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Abstract
Single-nucleotide polymorphisms (SNPs) in CYP2B6 have been shown to predict variation in plasma efavirenz
concentrations, but associations between these SNPs and efavirenz-mediated depression and viral suppression
are less well described. We evaluated three SNPs in CYP2B6 (rs3745274, rs28399499, and rs4803419) in
Ugandan persons living with HIV. To define exposure, we used previously published pharmacokinetic modeling
data to categorize participants as normal, intermediate, and poor efavirenz metabolizers. Our outcomes were
probable depression in the first 2 years after antiretroviral therapy (ART) initiation (mean score of >1.75 on the
Hopkins Symptom Depression Checklist) and viral suppression 6 months after ART initiation. We fit gener-
alized estimating equation and modified Poisson regression models adjusted for demographic, clinical, and
psychosocial characteristics with or without individuals with depression at the time of ART initiation. Among
242 participants, there were no differences in the pre-ART depression or viral load by efavirenz metabolism
strata ( p > .05). Participants were classified as normal (32%), intermediate (50%), and poor (18%) metabolizers.
Seven percent (56/242) of follow-up visits met criteria for depression. Eighty-five percent (167/202) of par-
ticipants who completed a 6-month visit achieved viral suppression. CYP2B6 metabolizer strata did not have a
statistically significant association with either depression [adjusted risk ratio (aRR) comparing intermediate or
poor vs. normal, 1.46; 95% confidence interval (CI), 0.72–2.95] or 6-month viral suppression (aRR, 1.01; 95%
CI, 0.88–1.15). However, in analyses restricted to participants without pre-ART depression, poorer CYP2B6
metabolism was associated with increased odds of depression (adjusted odds ratio, 4.11; 95% CI, 1.04–16.20).
Efavirenz-metabolizing allele patterns are strongly associated with risk of incident depression. Future work
should elucidate further region-specific gene–environment interactions and whether alternate polymorphisms
may be associated with efavirenz metabolism.
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Introduction
Efavirenz (EFV) is widely used as a first-line anti-retroviral therapy (ART) agent in sub-Saharan Africa,
where 70% of persons livingwith HIV (PLHIV) reside.1 There
is wide between-patient variability in the metabolism of efa-
virenz, spanning almost two orders of magnitude of con-
centration in controlled pharmacokinetic studies conducted
largely in high-income countries.2–4
Approximately 90% of the active form of efavirenz are
inactivated by the cytochrome P450 enzyme CYP2B6.5 Three
single-nucleotide polymorphisms (SNPs) in the gene have
been associated with efavirenz metabolism in populations
composed of participants of European and African descent
in resource-rich countries: 516G>T (rs3745274),6,7 983T>C
(rs28399499),8,9 and 15582C>T (rs4803419).9 These SNPs
are observed at minor allele frequencies of 23.6%, 0.0%, and
32.0%, respectively, in populations of European descent, and
37.4%, 8.2%, and 8.2%, respectively, in participants of
African descent, as shown in the 1000 Genomes project.10
In one multiethnic study including participants from Cau-
casian (50%), African (33%), and Hispanic (18%) descent,
the combination of these three genotypes predicted 33% of
the variation in trough efavirenz level variation.9 The asso-
ciation of rs3745274,11–13 rs28399499,13–15 and rs480341916
with lower efavirenz clearance has also been confirmed in
populations in sub-Saharan Africa, with one study in South
Africa estimating that the three genotypes predicted 34% of
the variation in mid-dose efavirenz concentrations.16
The variability in efavirenz levels due to CYP2B6 poly-
morphisms may have important clinical relevance for viro-
logic outcomes and the wide spectrum of neuropsychiatric
effects implicated in efavirenz use, including dizziness, in-
somnia, anxiety, headache, impaired concentration, suicidal
ideation, and depressive symptoms.17–19 However, there are
few data on relationships between these previously identified
allelic patterns and efavirenz-related clinical outcomes or
neuropsychiatric events in sub-Saharan Africa. One study in
Botswana showed an unexpected association between poorer
CYP2B6 metabolism alleles and lower central nervous sys-
tem (CNS) toxicity scores.20 In this analysis, we aimed to
estimate the association between CYP2B6 allele genotype
combinations and two treatment outcomes in participants of
African ancestry in Uganda: depression in the first 2 years
and viral suppression after 6 months of ART suppression with
an efavirenz-containing regimen in ART-naive individuals.
We hypothesized that genotypic combinations that have been
historically correlated with lower trough EFV levels (i.e.,
indicative of faster metabolism of EFV) would decrease the
risk of viral suppression. Conversely, we hypothesized that
genotypic combinations that historically correlated with
higher trough EFV levels (i.e., indicative of poorer metabo-
lism of EFV) would be correlated with increased reporting of
neuropsychiatric side effects.8,20–22
Methods
Study population, design, and data collection
Data for this study were pooled from two prospective co-
horts: the Uganda AIDS Rural Treatment Outcome Study
(UARTO, NCT01596322) and the Antiretrovirals in Kaposi
Sarcoma Study (ARKS, NCT00444379). The UARTO study
was an observational cohort of adult PLHIV recruited from
the Mbarara Regional Referral Hospital HIV Clinic at the
time of ART initiation.23,24 The ARKS study recruited adult
PLHIVwithmild-to-moderateKaposi sarcoma from a specialty
treatment center in Kampala (NCT00444379). Participants
were randomized to initiate ART with either efavirenz-based
or boosted protease inhibitor–based regimen. Participants un-
derwent a depression screen three to four times each year in the
UARTO cohort and three times each year in the ARKS cohort.
For the purposes of this analysis, only those visits in which the
participant was recorded as receiving EFV-based ART were
included in the longitudinal depression analysis, and only
those participants enrolled in the efavirenz arm were included
in the 6-month viral suppression analysis.
Outcomes
Our outcomes of interest were probable depression in the
first 2 years and viral suppression at 6 months after ART ini-
tiation. Viral suppression was defined as an undetectable viral
load, with limit of detection varying by type of assay. As viral
detection technology improved over the course of the UARTO
andARKS studies, the viral detection limit decreased from400
[Amplicor assay (Roche)] to 20 copies/mL [Cobas TaqMan
assay (Roche)]. Because study visits were not conducted ex-
actly at 3 month intervals, for the 6-month follow-up, we se-
lected the study visit closest to 6 months after ART initiation,
provided it was within the range of 3–9 months of follow-up.
Probable depression was defined with an adapted version of
the 15-item Hopkins Symptom Checklist Depression subscale
(HSCL-D),25 which we have previously validated among adult
PLHIV in Uganda.26–28 This adapted version adds a 16th item
(‘‘feeling like I don’t care about my health’’) to the instru-
ment.29 A participant was considered to have probable de-
pression if the mean score on the items was >1.75.30
Predictors
Our primary predictor of interest was the combination of
three CYP2B6 SNPs: rs3745274, rs28399499, and rs4803419.
IndividualCYP2B6 SNP genotype combinations were grouped
into three categories corresponding to normal, intermediate,
and poor EFV metabolizer phenotypes. These classifications
(Appendix Table 1) are based on previously published phar-
macokinetic modeling data9 and have been used in previous
studies.31,32 SNPs were genotyped as part of genome-wide
genotyping analyses performed at the RIKEN Center for
Genomic Medicine using the Human Omni Express Bead
Chip (Illumina, San Diego, CA) including over 700,000
SNPs.23 Two SNPs (rs3745274 and rs28399499) were directly
genotyped, whereas rs4803419 was imputed using the 1000
Genomes database. We performed quality control steps with
checks of identity-by-descent and sex.As previously described,
only imputed SNPs that passed quality control analyses with an
info score of >0.8 were included in the final analysis.23
Statistical models
We first characterized the distributions of variables at
baseline and compared them between participants of the three
EFV-metabolizing strata. Differences in continuous and cate-
gorical variables at baseline were tested by using the Wilcoxon
rank-sum and Pearson’s chi-square tests, respectively.
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We next estimated the minor allelic frequency of each SNP
in our cohort. We fit a Poisson regression model with robust
standard errors to estimate the association between EFV-
metabolizing strata and achievement of viral suppression at 6
months, specifying normal metabolizers as the referent ex-
posure category. We adjusted the model for demographic
variables, including age, sex, marital status, educational at-
tainment, household asset wealth, and year of study enroll-
ment. The index of household asset wealth was derived by
applying the method of principal component analysis to 25
household asset and housing characteristic variables as sug-
gested by Filmer and Pritchett.33 The first component was
extracted and used to define the index, which we then cate-
gorized into quintiles of relative household asset wealth. Year
of enrollment was included to adjust for secular trends,34
defined as a categorical variable with 3-year increments from
2005 until 2013, when enrollment concluded. We addition-
ally adjusted for pre-ART clinical variables, including
probable depression at enrollment, CD4+ T lymphocyte cell
count, viral suppression, ART duration, tuberculosis (TB)
coinfection, health status, and heavy alcohol use. ART du-
ration was measured as cumulative weeks since ART initia-
tion. TB coinfection was determined by a combination of
self-report and clinical record abstraction. Health status was
measured by the Physical Health Summary (PHS) score from
the Medical Outcome Survey-HIV (MOS-HIV) question-
naire and was categorized into quartiles.35 Heavy alcohol use
was determined by the three-item consumption subset of the
Alcohol Use Disorders Identification Test.36
We also fit generalized estimating equation (GEE) Poisson
regression models with an exchangeable correlation matrix
and cluster-correlated robust standard errors to estimate the
association between EFV-metabolizing strata and probable
depression. For this analysis, we used time-updated covari-
ates and restricted estimation to visits within 2 years of ART
initiation in the UARTO cohort and to the 1-year follow-up in
the ARKS cohort, as these were the minimum time period of
scheduled follow-up for all participants. In all the models, we
included a binary covariate for study (ARKS vs. UARTO) in
the model if its Wald p-value was <.25 in fully adjusted
models. We fit similar models for both viral suppression and
probable depression outcomes comparing slow and inter-
mediate metabolizers combined versus normal metabolizers.
We also fit models for probable depression excluding par-
ticipants with pre-ART baseline probable depression.
To graphically depict relationships between EFV-
metabolizing strata and depression symptom severity, we
modeled the association between metabolizer strata and de-
pressive symptom score using a mixed-effects linear regres-
sion model, adjusting for all aforementioned covariates (but
substituting pre-ART depressive symptom score for pre-ART
probable depression). The regression model also included
product terms for the interaction between EFV-metabolizing
strata and time on ART and a random intercept by participant.
We then used postestimation margins to plot the predicted
depression scores by visit for each metabolizer strata.
In post hoc exploratory analyses, we fit adjusted GEE lo-
gistic regression models estimating the association between
minor allele copy number and probable depression in the first 2
years for each SNP. Due to problems withmodel convergence,
we used a logistic instead of a Poisson regression model,
collapsed participants heterozygous or homozygous for the
minor allele into the same category (due to small counts in
each strata), and fit models with and without a exposure by
time interaction terms and plotted relationships with post-
estimation margins. We also fit adjusted mixed-effects linear
regression models and plotted predicted depression scores by
visit for each SNP. We further fit adjusted Poisson regression
models with robust standard errors estimating the association
between each of the SNP combinations and viral suppression
and plotted relationships with postestimation margins.9
Results
Of the 746 participants with genotype data, the minor al-
lelic frequencies for rs3745274, rs28399499, and rs4803419
were 34.7%, 7.1%, and 7.0%, respectively. A total of 242
participants taking efavirenz-based regimens met inclusion
criteria and were included in the final analysis of depression
(Appendix Fig. 1); of these, 202 participants had 6-month
data for the viral suppression analysis.
Of the 242 total participants in the depression analy-
tic sample, 78 (32.2%), 120 (49.6%), and 44 (18.2%) had
CYP2B6 genotypic combinations that corresponded to normal,
intermediate, and poor efavirenz-metabolizing strata, respec-
tively. Themedian age of the samplewas 35 years (interquartile
range [IQR], 29–42), and the median CD4+ T lymphocyte
count at enrollment was 160 cells/mm3 (IQR, 59–284). The
median log10 viral load at enrollment was 5.1 (IQR, 4.7–5.6).
Sixty-two participants (25.6%) screened positive for probable
depression at enrollment, and the median Hopkins Symptom
Checklist score was 1.38 (IQR, 1.12–1.82).
There were no pre-ART differences between the three
strata in any of the factors measured, including CD4+ T
lymphocyte count, viral load, probable depression, and de-
pressive symptom score (all p > .05; Table 1). There were a
larger proportion of total visits missed in the normal meta-
bolizer strata than the intermediate or poor strata (8.5%,
5.0%, and 5.1% of visits, respectively; p = .040). There was
no statistically significant difference in the proportions of
participants lost to follow-up, which was defined as having
the last study visit more than 6 months before the end of 2-
year right censoring in the UARTO study or less than 3
months before the end of the 1-year ARKS study ( p = .11).
Primary analyses
The 242 participants contributed a total of 1,021 follow-up
study visits. At 53 visits (6.7%), there was a positive screen
for probable depression. The adjusted risk ratio (aRR) of
probable depression for participants in the intermediate me-
tabolism strata compared with the normal strata was 1.53
(95% confidence interval [CI], 0.75–3.12; Table 2). The aRR
for those in the poor strata compared with the normal strata
was 1.19 (95% CI, 0.42–3.33). There was a nonsignificant
stepwise association between poorer metabolizer strata and
higher predicted mean depressive at symptom scores at 3
months that dissipated over time (Fig. 1). In analyses re-
stricted to participants without pre-ART probable depression
(180/242 participants), the adjusted odds ratio (aOR) of
probable depression for participants in the intermediate me-
tabolism strata compared with the normal strata was 4.15
(95% CI, 1.05–16.51) and 3.86 (95% CI, 0.65–22.99) for the
poor strata compared with the normal strata (Table 2).
984 CHANG ET AL.
D
ow
nl
oa
de
d 
by
 U
cs
f L
ib
ra
ry
 U
ni
ve
rs
ity
 o
f C
al
ifo
rn
ia
 S
an
 F
ra
nc
isc
o 
fro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
7/
12
/1
9.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Approximately 82% (167/202) of participants achieved
viral suppression at 6 months. In the adjusted model, the
aRR of 6-month viral suppression for participants in the
intermediate metabolism strata compared with the normal
strata was 1.01 (95% CI, 0.99–1.17; Table 3) and 1.04
(95% CI 0.85–1.26) in the poor versus normal strata. Re-
sults were similar when comparing combined slow and
intermediate metabolizers versus normal metabolizers for
both probable depression and viral suppression outcomes
(Tables 2 and 3).
Table 1. Summary Characteristics for Study Cohort at Enrollment
Variable
Metabolizer level
pNormal (n = 78) Intermediate (n= 120) Poor (n = 44)
Demographic characteristics
Age (years), median (IQR) 35 (29, 41) 35 (28, 43) 35 (30, 44) .87
Female, n (%) 40 (51.3%) 65 (54.2%) 21 (47.7%) .75
Married, n (%) 50 (64.1%) 71 (59.2%) 27 (61.4%) .78
Secondary education, n (%) 27 (34.6%) 46 (38.3%) 15 (34.1%) .82
Asset index, n (%)
1st quintile (most poor) 13 (16.7%) 17 (14.2%) 9 (20.5%) .97
2nd quintile 14 (17.9%) 26 (21.7%) 8 (18.2%)
3rd quintile 17 (21.8%) 22 (18.3%) 9 (20.5%)
4th quintile 14 (17.9%) 27 (22.5%) 8 (18.2%)
5th quintile (least poor) 20 (25.6%) 28 (23.3%) 10 (22.7%)
Year of enrollment
2005–2007 24 (30.8%) 28 (23.3%) 13 (29.5%) .81
2008–2010 32 (41.0%) 53 (44.2%) 18 (40.9%)
2011–2013 22 (28.2%) 39 (32.5%) 13 (29.5%)
Clinical characteristics
CD4 count (cells/mm3), median (IQR) 159 (56, 278) 173 (68, 289) 132 (60, 256) .70
Viral load (log10 copies/mL), median (IQR) 5.1 (4.6, 5.4) 5.2 (4.7, 5.6) 5.3 (4.9, 5.8) .068
Depressed, n (%) 19 (24.4%) 32 (26.7%) 11 (25.0%) .93
Depressive symptom score, median (IQR) 1.41 (1.19, 1.75) 1.38 (1.12, 1.88) 1.38 (1.12, 1.78) .89
Physical health summary score, n (%) .36
1st quartile (least healthy) 38 (49.4%) 63 (52.5%) 28 (65.1%)
2nd quartile 25 (32.5%) 28 (23.3%) 8 (18.6%)
3rd quartile 8 (10.4%) 19 (15.8%) 6 (14.0%)
4th quartile (most healthy) 6 (7.8%) 10 (8.3%) 1 (2.3%)
Heavy drinking, n (%) 14 (28%) 12 (16%) 3 (12%) .15
Follow-up characteristics
Enrolled in the ARKS study 27 (34.6%) 44 (36.7%) 18 (40.9%) .79
No. of visits per participant, median (IQR) 6 (4,7) 7 (4,7) 7 (4,7) .62
Total No. of visits missed, n (%) 38 (8.5%) 36 (5.0%) 13 (5.1%) .040
Participants lost to follow-up, n (%) 1 (1.3%) 2 (1.7%) 3 (6.8%) .11
Table 2. Generalized Estimated Equations Regression Estimates for Probable
Depression by Metabolizer Strata
Strata
All participants (n= 242)
Excluding participants with pre-ART
probable depression (n = 180)
Unadjusted RR
(95% CI) p
Adjusted RRa
(95% CI) p
Unadjusted OR
(95% CI) p
Adjusted ORb
(95% CI) p
Normal REF — REF — REF — REF —
Intermediate 1.80 (0.78–4.15) .170 1.53 (0.75–3.12) .24 3.97 (0.83–19.05) .084 4.15 (1.05–16.51) .043
Poor 1.63 (0.61–4.30) .33 1.19 (0.42–3.33) .75 5.17 (0.99–26.96) .051 3.86 (0.65–22.99) .137
Normal REF — REF — REF — REF —
Intermediate or poor 1.75 (0.79–3.90) .171 1.46 (0.72–2.95) .30 4.29 (0.95–19.32) .058 4.11 (1.04–16.20) .043
aAdjusted for baseline depression, baseline suicidal ideation, sex, year of enrollment, time-updated age, marital status, education, asset
index, CD4+ T lymphocyte count, viral suppression, health status, and heavy drinking.
bAdjusted for sex, year of enrollment, time-updated age, marital status, education, asset index, CD4+ T lymphocyte count, viral
suppression, and health status. Not adjusted for baseline suicidal ideation or heavy drinking, as these variables were too collinear with the
outcome. Third and fourth quartiles of health status score were also collapsed due to zero counts in the fourth quartile. Logistic regression
was used due to problems with convergence with Poisson regression.
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Exploratory analyses
In post hoc GEE regression analyses, ‡1 copy of the allele
copy number for the rs4803419 allele was associated with a
nonsignificant decreased risk of probable depression (aOR,
0.27; 95%CI, 0.48–1.47). After graphical exploration and the
inclusion of a allele-by-time interaction term (Wald p-value
for interaction = .004), ‡1 copy of the rs4803419 allele was
significantly associated with a decreased risk of probable
depression before 1 year of follow-up but converged to have
similar risk compared with those with wild-type alleles at
later follow-up times (Appendix Tables 2 and 3, Appendix
Fig. 2). In the adjusted mixed-effects regression models, we
estimated no statistically significant difference between de-
pressive symptom score over time (Appendix Fig. 3).We also
estimated no statistically significant association between
minor allele copy number and viral suppression for each of
the SNP (all p > .20; Appendix Table 4; Appendix Fig. 4).
Discussion
In this pooled analysis of data on African adult PLHIV on
EFV-containing ART participating in prospective cohort and
experimental studies conducted in Uganda, we found that
CYP2B6 polymorphisms associated with poorer EFV me-
tabolism was significantly associated with an approximately
fourfold increase in the odds of probable depression in those
without pre-ART baseline probable depression but not in the
cohort as a whole, which may have important therapeutic
implications for patients starting ART in the region.
Prior studies about the relationship between EFV-
metabolizing genotypes and CNS adverse effects have
been conflicting; some have reported an association between
poor efavirenz-metabolizing genotypes and increased CNS
toxicity in participants of both Caucasian and African an-
cestry,6,37 whereas others have found no significant associ-
ation between CYP2B6 genotype and increased risk of
various symptoms of CNS toxicity among participants of
African origin.8,20,22 In our study, we hypothesize that we
were only able to observe a statistically significant relation-
ship in those without depression at baseline because there
may be other much stronger predictors of depression in those
with pre-ART baseline depression that might modify and
mask this association.
We did also observe a nonsignificant association between
poorer metabolism strata and higher predicted depressive
symptom scores at 3 months that dissipated with longer
follow-up; this could be consistent with studies showing at-
tenuation of neuropsychiatric effects with prolonged EFV
use,38 although other studies suggest that EFV could have
longer term neuropsychiatric effects.18,39
In post hoc analyses in which the SNPs were evaluated
individually, we found no evidence of an association between
poor-metabolizing SNPs and increased risk of probable de-
pression in all participants. In contrast, we found some evi-
dence in a post hoc analysis that ‡1 copy of the rs4803419
allele, a SNP that has been associated with poor metabolism
in both Caucasian and African populations,9,16 may be as-
sociated with a lower odds of depression in the first year of
follow-up after starting efavirenz-containing ART compared
with those with no copies of the minor allele. This unex-
pected, inverse association is similar to that found in a cohort
study in Botswana, in which Gross et al. found an association
FIG. 1. Model-adjusted predicted depres-
sive symptom scores over visits by meta-
bolizer strata.
Table 3. Poisson Regression Model Estimates
for 6-Month Viral Suppression
by Metabolizer Strata
Strata
Unadjusted RR
(95% CI) p
Adjusted RRa
(95% CI) p
Normal REF — REF —
Intermediate 1.03 (0.89–1.19) .70 1.01 (0.88–1.15) .94
Poor 1.01 (0.84–1.22) .92 1.00 (0.83–1.22) .96
Normal REF — REF —
Intermediate
or poor
1.02 (0.89–1.18) .74 1.01 (0.88–1.15) .94
aAdjusted for the following baseline covariates: age, sex, marital
status, education, asset index, year of enrollment, CD4+ T lympho-
cyte count, log10 viral load, probable depression, health status, heavy
drinking, and study data source.
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between a composite exposure of two SNPs examined in this
study (rs3745274 and rs28399499) and both lower efavirenz
clearance and a lower CNS adverse experience score.20
However, we note that the association between rs4803419
and CNS adverse effects is not well established, has unclear
biological or pharmacologic plausibility, and that additional
data are needed to better elucidate these relationships.
The evidence is also conflicting for the association of
CYP2B6 alleles and virologic outcomes. Ribaudo et al. found
an inverse association between the presence of the rs3745274
allele and virologic failure in a subgroup analysis of African
Americans.8 However, other studies, including ours, have not
corroborated this finding.20,31
Limitations of this study include lack of pharmacokinetic
measures of efavirenz metabolism to support mechanistic
relationships between allelic patterns and our clinical out-
comes. In addition, we only assessed three SNPs within the
CYP2B6 gene; other polymorphisms including rare or novel
variants identified by genetic sequencing, rather than gen-
otyping, might be able to identify a more detailed associa-
tion between this gene and viral suppression and probable
depression. Nonetheless, these three SNPs have been re-
ported to explain approximately one third of the variability
in efavirenz concentrations in both studies in the United
States and South Africa,9,16 and although we did not have
genetic sequencing data, imputation was performed to es-
timate one of the three SNPs that was not directly geno-
typed. We may also have limited power for assessing our
outcomes, given our sample size and outcome distribution.
There is also potential for measurement bias given that
depression symptoms severity was assessed by participant
self-report rather than observer rating. However, previous
studies have found this measure to be valid and reliable
when administered to study participants in rural Uganda.26–
28 There is also potential for observational bias in our study,
given the differential proportion of missed visits among the
metabolism strata in our studies. However, the proportion of
missed visits was relatively small (<10% of all visits missed
in all strata).
In summary, we found a strong association between efa-
virenz metabolism–determining CYP2B6 genotypic com-
binations and probable depression in the first 2 years among
participants without depression at baseline and no associ-
ation with viral suppression at 6 months. Future work
should reassess these relationships with pharmacologic data
and explore other potential gene–environment interactions
that may be associated with efavirenz metabolism in this
population.
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Appendix Table 1. Definitions of Metabolizer Categories and Number
of Participants with Each SNP Combination
SNP
Allele copy numbers defining each SNP
combination and metabolizer category
Fast Intermediate Slow Not categorizeda
Ordinal level of EFV metabolismb
(1= fastest, 10 = slowest)
1 2 3 4 5 6 7 8 9 10 — —
rs3745274 (516G>T) 0 0 0 1 0 1 0 2 1 0 1 1
rs28399499 (983T>C) 0 0 0 0 1 0 1 0 1 2 0 1
rs4803419 (15582C>T) 0 1 2 0 0 1 1 0 0 0 2 1
No. of participants in whole study
by SNP combination
206 45 6 249 59 43 2 91 42 1 1 1
No. of participants in final cohort
by SNP combination
69 9 2 77 22 18 0 30 14 0 1c 0d
aTwo SNP combinations were unable to be categorized as fast, intermediate, or slow based on the previously published pharmacokinetic
framework,10 and metabolizer strata were imputed for these SNP combinations.
bBased on previously published pharmacokinetic modeling study by Holzinger et al.9
cImputed as intermediate metabolize.
dImputed as slow metabolizer.
SNP, single-nucleotide polymorphism.
Appendix Table 2. GEE Logistic Regression Models for Depression by the Presence
of rs3745274, rs28399499, and rs4803419 Minor Alleles
No. of copies minor allele
Unadjusted
OR (95% CI) p
Adjusted
ORa (95% CI) p
Wald p-value for added
allele · time interaction term
By the presence of rs3745274 allele
0 REF — REF — .79
1 or 2 1.28 (0.63–2.63) .49 1.03 (0.49–2.19) .93
By the presence of rs28399499 allele
0 REF — REF — .36
1 or 2 1.42 (0.66–3.09) .37 1.34 (0.59–3.08) .48
By the presence of rs4803419 allele
0 REF — REF — .004
1 or 2 0.43 (0.06–3.22) .41 0.27 (0.48–1.47) .129
aEstimated OR based on main effects model adjusted for the following baseline covariates: age, sex, marital status, education, asset index,
year of enrollment, CD4+ T lymphocyte count, log10 viral load, probable depression, health status, heavy drinking, and study data source.
OR, odds ratio.
Appendix Table 3. Crude Risk of Depression by the Presence of rs4803419 Minor Allele Over Time
No. of copies
minor allele
No. of depressed/no. of participants (%) stratified by time on antiretroviral therapy
Baseline 3 months 6 months 9 months 12 months 15 months 18 months 21 months
0 33/110
(30%)
15/176
(8.5%)
7/150
(4.46%)
6/73
(7.6%)
10/163
(5.8%)
13/112
(10.4%)
3/117
(2.5%)
7/100
(7.0%)
1 or 2 3/14
(21.4%)
0/23
(0.0%)
0/19
(0.0%)
0/14
(0.0%)
1/23
(4.3%)
2/13
(15.4%)
0/17
(0.0%)
1/13
(7.7%)
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Appendix Table 4. Modified Poisson Regression
Models for Viral Suppression by rs3745274,
rs28399499, and rs4803419 Minor
Allele Copy Number
No. of
copies
Unadjusted
RR (95% CI) p
Adjusteda
RR (95% CI) p
By rs3745274 allele copy number
0 REF — REF —
1 1.01 (0.88–1.15) .92 1.00 (0.88–1.14) .96
2 1.03 (0.85–1.25) .75 1.04 (0.85–1.28) .69
By rs28399499 allele copy number
0 REF — REF —
1 0.95 (0.79–1.15) 0.95 (0.79–1.14) .56
2 —b — — —
By rs4803419 allele copy number
0 REF — REF —
1 0.84 (0.62–1.13) .24 0.85 (0.65–1.11) .24
2 1.20 (1.12–1.28) <.001 1.09 (0.95–1.24) .239
aAdjusted for the following baseline covariates: age, sex, marital
status, education, asset index, year of enrollment, CD4+ T lympho-
cyte count, log10 viral load, probable depression, health status, heavy
drinking, and study data source.
bNo participants with two copies of rs28399499 minor allele.
RR, risk ratio.
APPENDIX FIG. 1. Flow chart for
included participants.
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APPENDIX FIG. 2. Model-adjusted pre-
dicted probability of probable depression by
copy number of rs4803419 minor alleles
with exposure by time interaction term.
APPENDIX FIG. 3. Predicted depression scores over visits by copy number of (A) rs3745274, (B) rs28399499, and (C)
rs4803419 minor alleles.
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APPENDIX FIG. 4. Adjusted risk of
viral suppression by allele combinations.
N/A, not categorized byHolzinger et al9;
*Too few observations (n£1).
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